GleamWall
中文EN

XBIT XBiotech Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1626878 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-49.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-29.9%
ROA-29.0%
ROIC (approx.)-193.7%
Asset turnover—

Leverage & solvency

Liabilities / assets3.5%
Debt / equity0.00x
Current ratio39.51x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.94x
Accruals ratio-1.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$47.39M$37.76M
SG&A expense$8.29M$4.71M
Operating income-$55.69M-$42.47M
Pretax income-$45.30M-$38.56M
Income tax$235,000-$32,000
Net income-$45.54M-$38.53M
EBITDA-$54.00M-$40.73M
EPS (basic)-1.49-1.26
EPS (diluted)-1.49-1.26
Weighted avg. shares (diluted)30.49M30.46M
Balance sheet
Cash & equivalents$125.55M$172.68M
Receivables—$700,000
Current assets$126.95M$174.57M
PP&E, net$23.13M$24.53M
Total assets$150.08M$199.09M
Current liabilities$7.93M$15.11M
Total liabilities$9.73M$16.82M
Shareholders' equity$140.35M$182.27M
Shares outstanding30.49M30.49M
Cash flow statement
Operating cash flow-$39.92M-$30.96M
Capital expenditure$289,000$1.30M
Free cash flow-$40.21M-$32.27M
Investing cash flow-$289,000-$1.30M
Financing cash flow-$10.25M$10.45M
Depreciation & amortization$1.69M$1.75M
Stock-based compensation$3.62M$1.75M
Share buybacks—$0

Free plan shows the latest 2 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.